NCT07862582

RYZ711 Diagnostic Platform Study

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2026-10Est. Completion: 2027-12

Enrollment target: 116 participants

Locations

Research Facility, Omaha, Nebraska, United States

Contact

RayzeBio Clinical Trialsclinicaltrials@rayzebio.com +1 619 657 0057

Anthony A Golsorkhi, MD, Study Director, RayzeBio, Inc, MD Study Director

Other microbiome trials you might be interested in

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerPhase 1Recruiting

Head and Neck CancerHead and Neck Squamous Cell CarcinomaParanasal Sinus NeoplasmsNasopharyngeal CarcinomaOropharyngeal Squamous Cell CarcinomaHypopharyngeal CancerCarcinoma of LarynxOral Squamous Cell CarcinomaSalivary Gland CancerAdenoid Cystic CarcinomaProstate CancerMetastatic Castration Resistant Prostate Cancer

Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat,…

Bethesda, United StatesEst. completion Oct 1, 2036

View Trial →

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.